Skip to main content
Dryad

Ocular graft vs host disease mouse model

Data files

Dec 30, 2022 version files 119.71 KB

Abstract

Ocular graft versus host disease (OGvHD) develops in nearly 50% of patients after allogeneic hematopoietic stem cell transplantation (HSCT) and frequently manifests as dry eye disease (DED).  The aim of this study was to evaluate the efficacy of a single subconjunctival (SCJ) dose of adeno-associated virus (AAV) gene therapy encoding human leukocyte antigen G (HLA-G) isoforms 1 and 5 to induce ocular immune tolerance and inhibit development of clinical signs of OGvHD.